Ensysce Biosciences, Inc. 8-K

What Happened
Ensysce Biosciences, Inc. announced its financial results for the fiscal quarter and fiscal year ended December 31, 2025 in a press release issued and filed on March 30, 2026. The company disclosed this information in a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition), and attached the press release as Exhibit 99.1.

Key Details

• Filed Form 8-K on March 30, 2026 reporting results for the period ended December 31, 2025.
• The announcement was made via a press release included as Exhibit 99.1 to the 8-K.
• The filing also includes the Inline XBRL cover page (Exhibit 104).

Why It Matters
This 8-K provides the company’s latest reported quarterly and full-year results—key information investors use to assess recent performance, revenue trends, profitability, and cash position. Retail investors should read the attached press release for the specific financial metrics (revenue, net income/loss, cash balance, and any commentary on operations or guidance) and watch for subsequent SEC filings (e.g., 10-K or 10-Q) for full financial statements and management discussion.